Unichem Laboratories Ltd

NSE: UNICHEMLAB · Pharmaceuticals · sector

₹474.65NSE close 2026-10-26

Key numbers

Market cap₹3,342 cr

Price₹474.65

52w high / low₹687 / ₹278

P/E10.8xSector median 27.9x

P/B1.2xSector median 2.9x

Book value₹386.0

Dividend yield–Sector median 0.48%

ROE11.8%Sector median 11.7%

ROCE12.0%Sector median 12.3%

OPM18.8%Sector median 14.0%

Debt / equity0.17xSector median 0.16x

EV/EBITDA8.1xSector median 18.6x

Interest cover12.1x

Current ratio2.48x

Sales growth 3y+17.9%Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG0.08x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹295 cr vs borrowings ₹469 cr (FY26): borrowings are higher by ₹174 cr.
Operating profit covered interest 12.1x in the last 12 months.
No promoter shares are pledged.
Operating cash flow was below net profit in 3 of the last 5 years (FY26, FY25, FY22).
Net loss in 2 of the last 8 quarters.
Revenue was higher than a year earlier in 2 of the last 4 quarters.
Other income was 24% of net profit in the last 12 months.
Dividend paid in 2 of the last 5 financial years.
Price ₹474.65 on 2026-10-26: -30.9% from the 52-week high, +70.6% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹877.05 · low ₹298.20

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	462	533	587	527	579	521	575	633
EBITDA	58	86	84	22	8	320	35	70
OPM %	12.4%	16.0%	14.3%	4.3%	1.4%	61.5%	6.1%	11.1%
Other income	9	14	9	7	21	12	23	16
Net profit	30	58	53	-10	-12	264	11	41
EPS (₹)	4.34	8.22	7.52	-1.49	-1.69	37.54	1.55	6.61
Revenue YoY					+25.3%	-2.2%	-2.1%	+20.1%
Profit YoY					-139.0%	+356.9%	-79.4%	–

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	1,270	1,343	1,705	2,111	2,202	2,308
EBITDA	73	-84	43	265	386	433
Net profit	33	-202	-70	138	253	305
EPS (₹)	4.70	-28.72	-10.01	19.53	35.91	44.01
Revenue growth		+5.8%	+26.9%	+23.8%	+4.3%	+9.4%
Profit growth		-711.7%	–	–	+83.9%	+132.9%
Dividend / share (₹)	4.00	4.00	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+17.9%	+12.3%	+9.4%
Net profit	–	+49.1%	+132.9%
EPS	–	+49.1%	–
Share price	–	-18.4% (2y)	+8.7%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	2,435	2,362	2,451	2,717
Borrowings	–	297	219	430	469
Cash & equivalents	–	187	156	118	295
Total assets	–	3,193	3,169	3,569	3,737
Fixed assets	–	1,255	1,194	1,279	1,204
Capital work in progress	–	147	123	31	100
Investments	–	0	0	0	0
Receivables	–	589	610	779	829
Inventory	–	625	705	989	975
Payables	–	291	299	403	357

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	-260	-85	17	-7	4
Cash from investing	100	203	50	-241	192
Cash from financing	191	-81	-106	184	2
Capex	127	44	23	137	123
Free cash flow	-387	-129	-6	-144	-119

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	-8.3%	-3.0%	5.6%	9.3%
ROCE %	–	-5.8%	-1.5%	6.1%	10.2%
Debtor days	–	160	131	135	137
Inventory days	–	414	387	418	349
Payable days	–	193	164	170	128
Cash conversion cycle (days)	–	381	354	383	358
Working capital days	–	258	211	179	217

Shareholding

Holder	% (2026-09-30)
Promoters	70.22%
FIIs	2.70%
DIIs	9.40%
of which Mutual funds	8.65%
of which Insurance	0.22%
Public (non-institutions)	17.68%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%

Promoter group	%
Ipca Laboratories Limited	52.67%
Dr. Prakash Amrut Mody	12.78%
Anita Prakash Mody	1.88%
Suparna Prakash Mody	1.35%
Supriya Prakash Mody	1.35%
Dr. Prakash Amrut Mody - Suparna Mody Trust (Promoter Trust )	0.07%
Dr. Prakash Amrut Mody - Supriya Mody Trust (Promoter Trust)	0.06%
Dr. Prakash Amrut Mody - Shwetambari Mody Trust (Promoter Trust)	0.06%

Public holders above 1%	%
Hdfc Small Cap Fund	7.04%
Dsp Healthcare Fund	1.60%
Polunin Emerging Markets Small Cap Fund, Llc	1.58%
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs	1.06%

26,164 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
UNICHEMLAB	₹3,342 cr	10.8x	1.2x	11.8%	12.0%	18.8%	+17.9%	–

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2022-08-01	Dividend	Annual General Meeting/Dividend - Rs 4 Per Share
2021-07-22	Dividend	Annual General Meeting/Dividend - Rs 4 Per Share
2020-08-20	Dividend	Annual General Meeting/Dividend - Rs 4 Per Share
2019-07-18	Dividend	Annual General Meeting/Dividend - Rs 4 Per Share
2018-07-19	Dividend	Annual General Meeting/Dividend- Rs 5 Per Share
2018-02-15	Buyback	Buyback
2017-07-13	Dividend	Annual General Meeting/Dividend - Rs 3/- Per Share
2016-07-14	Other	Annual General Meeting
2016-03-17	Dividend	Interim Dividend - Rs 2/- Per Share
2015-07-02	Dividend	Annual General Meeting/Dividend - Rs 2/- Per Share
2014-07-03	Dividend	Annual General Meeting/Dividend Rs 4/- Per Share
2014-01-23	Dividend	Interim Dividend Rs.4/- Per Share (Purpose Revised)
2013-07-11	Dividend	Annual General Meeting/Dividend Rs 4.50 Per Equity Share
2012-09-13	Dividend	Annual General Meeting And Dividend Rs.3/- Per Share
2011-07-14	Dividend	Annual General Meeting And Dividend Rs.2.80 Per Share
2010-10-21	Split	Interim Dividend Rs.3/- Per Share And Face Value Split From Rs.5/- To Rs.2/- (Purpose Revised)
2010-09-08	Other	Annual General Meeting
2010-05-14	Dividend	2nd Interim Dividend-Rs.7/- Per Share (Purpose Revised)
2009-10-27	Dividend	Interim Dividend
2009-07-09	Other	Agm/Div-Rs.5/- Per Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacture and Sale of pharmaceutical products: Drugs and Pharmaceuticals


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	UNICHEMLAB
BSE code	506690
ISIN	INE351A01035
Face value	₹2.0
Incorporated	1962-08-22
Website	www.unichemlabs.com
Plants (India / abroad)	6 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.